Loading
Latest filing published 11 Oct 2023 for Zynerba Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Terri B. Sebree in Zynerba Pharmaceuticals, Inc., where the filings describe the role as chief executive. The record holds 7 filings, for trades running from 26 January 2022 to 10 October 2023.
The open-market record consists of 1 sale worth €14k, with no purchase. Outside the open market, there are 5 share grants. 2023 to date brings no purchases and 1 sale.
The record was last updated on 11 October 2023 with a transaction in Zynerba Pharmaceuticals, Inc. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations